Sanofi SA said on Wednesday that it has signed an agreement with BioNTech SE to support the manufacture and supply of the coronavirus vaccine it is developing in conjunction with Pfizer Inc.
The French pharmacist said he will provide BioNTech with access to its production infrastructure to supply more than 125 million doses of vaccines to the European Union. Initial supplies will come from Sanofi’s Frankfurt facility beginning in the summer of 2021, he said.
Sanofi added that it is continuing to develop two vaccine candidates against Covid-19, saying that in February 2021 it plans to start a new Phase 2 study of the recombinant protein-based vaccine it is developing with GlaxoSmithKline PLC. The company is also developing a messenger RNA vaccine in partnership with Translate Bio Inc., he said.
Write to Cecilia Butini at [email protected]